| Literature DB >> 30182049 |
Cynthia Kanagaratham1, Benjamin F Sallis1, Edda Fiebiger1.
Abstract
Immunoglobulin E-mediated food allergy is rapidly developing into a global health problem. Publicly available therapeutic intervention strategies are currently restricted to allergen avoidance and emergency treatments. To gain a better understanding of the disease pathophysiology so that new therapies can be developed, major research efforts have been put into studying food allergy in mice. Animal models should reflect the human pathology as closely as possible to allow for a rapid translation of basic science observations to the bedside. In this regard, experimental models of food allergy provide significant challenges for research because of discrepancies between the presentation of disease in humans and mice. The goal of this review is to give a summary of commonly used murine disease models and to discuss how they relate to the human condition. We will focus on epicutaneous sensitization models, on mouse strains that sensitize spontaneously to food as seen in humans, and on models in humanized animals. In summary, expanding the research toolbox of experimental food allergy provides an important step toward closing gaps in our understanding of the derailing immune mechanism that underlies the human disease. The availability of additional experimental models will provide exciting opportunities to discover new intervention points for the treatment of food allergies. (Cell Mol Gastroenterol Hepatol 2018;x:x).Entities:
Keywords: Allergen Challenge; Allergen Sensitization; Anaphylaxis; EPIT, epicutaneous immunotherapy; Epictutaneous Sensitization; FCER1A, high-affinity immunoglobulin epsilon receptor subunit alpha; FCERIA; FcεRI, high-affinity immunoglobulin E receptor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HSC, hematopoietic stem cell; Humanized Model; IL, interleukin; Ig, immunoglobulin; IgE; LCT, long chain triglycerides; MCPT, mouse mast cell protease; MCT, medium chain triglycerides; Murine Models of Food Allergy; OIT, oral immunotherapy; PBMC, peripheral blood mononuclear cell; Spontaneous Sensitization; TSLP, thymic stromal lymphopoietin; Th, T helper; Treg, regulatory T cell; WASP, Wiskott–Aldrich syndrome protein
Mesh:
Substances:
Year: 2018 PMID: 30182049 PMCID: PMC6121159 DOI: 10.1016/j.jcmgh.2018.05.010
Source DB: PubMed Journal: Cell Mol Gastroenterol Hepatol ISSN: 2352-345X
Adjuvant-free and Spontaneously Sensitizing Murine Models of Food Allergy
| Strain | Description | Sensitization | Challenge | Phenotype of allergic mice | Reference |
|---|---|---|---|---|---|
| Epicutaneous and adjuvant-free models | |||||
| BALB/c | Inbred strain | Days 0, 4, 8, and 12: id 5 μg rTLSP and 10 μg OVA | Days 17–22: daily ig 50 mg OVA | Acute diarrhea symptoms starting from third challenge Infiltration of inflammatory cells into the jejunum Elevated OVA-IgE, Decrease in core body temperature | |
| BALB/c | Inbred strain | Days 0, 3, and 6: 100 μg OVA or peanut protein applied to tape stripped skin on a patch | Day 9: ig 100 mg OVA or ig 50 μg peanut protein | Increase in allergen-specific IgE, Expansion of mast cells in the jejunum Increase in | |
| Intragastric and adjuvant-free models | |||||
| IL4RF709 | Substitution of tyrosine (Y) for phenylalanine (F) at position 709 of IL4Rα | Week 0: ig 5 mg OVA on days 0, 1, 2, and 7 | Week 9: ig 150 mg OVA | Decrease in core body temperature Diarrhea Increase in serum total IgE, OVA-IgE, OVA-IgG1, and MCPT1 | |
| Weeks 0–8: ig 100 μg OVA weekly | Week 9: 150 mg OVA | Decrease in core body temperature Edema and mast cell expansion in the small intestine Increase in serum total IgE, OVA-IgE, and MCPT1 Specific microbiome signature associated with allergen exposure | |||
| Weeks 1–4: ig 5 mg peanut protein weekly | Week 5: ig 100 mg peanut protein | Increase in serum MCPT1, IgE, and peanut-specific IgE and IgG1 Increase in IL-4 secreting CD4+ T cells in MLNs and spleen Decreased number of Foxp3+ Tregs in colon Allergen induced proliferation of Foxp3+ Tregs Increase in Increase in ILC2 and ILC3 in MLNs | |||
| WASP deficient (Was-/- on BALB/c background) | Targeted mutation in | Days 0, 5, 10, 15, 20, 25, 30, and 35: ig 5 mg OVA | Day 49: ig 50 mg OVA | Increase in total serum IgE and OVA-IgE, and MCPT1 Allergic diarrhea Intestinal mast cell expansion | |
| C3H/HeJ | Inbred strains | Acute: ig 80 mg peanut protein or 60 mg OVA with MCT oil | None | Acute and chronic: increase in antigen-specific IgE and IgG in the serum Chronic: increase in | |
| Balb/c | Inbred strain | Days 0 and 3: ig MCT administration | None | Decrease in core body temperature Increase in serum egg white specific IgE, MCPT1, IL4, and IL13 Increase in number of mast cells, eosinophils, and dendritic cells in the lamina propria | |
| Spontaneous sensitization models | |||||
| CNS1 knockout | Deficient in CNS1 | Spontaneous sensitization to chow | None | Th2 skewed Tregs (GATA3+) Increase in Th2 cytokine production by CD4+ T cells (IL4, IL5, IL13) | |
| WASP deficient (Was-/- on C57BL/6J background) | Targeted mutation in | Spontaneous sensitization to wheat and soy in chow | None | High serum levels of IgE and MCPT1 Intestinal inflammation Expansion of mast cells in the small intestine Proliferation of CD4+ T cells in MLNs Th2 skewed Tregs (GATA3+) | |
| Wasfl/fl Foxp3-Cre | Targeted mutation in | ||||
id, intradermal; ig, intragastric; ip, intraperitoneal; ILC, innate lymphoid cell; MCPT1, mast cell protease 1; MLNs, mesenteric lymph nodes; OVA, ovalbumin; rTSLP, recombinant thymic stromal lymphopoietin; Was, Wiskott-Aldrich syndrome.
Humanized Murine Models of Food Allergy
| Strain | Description | Engraftment | Sensitization | Challenge | Phenotypes | Reference |
|---|---|---|---|---|---|---|
| NOD-scid-γc−/− (NSG) | NOD-SCID mice with targeted mutation in IL2 receptor γ-chain | ip: 2 × 107 PBMCs from food allergic donors with 20 μg allergen (birch pollen, grass pollen, or hazelnut) | None | Oral or rectal with the same allergen given during the engraftment | Production of allergen-specific IgE Allergen induced proliferation and cytokine production of splenic CD4+ T cells Inflammation in the colon – mucosal hypertrophy, enhanced wall thickening, infiltration of mucosa with mononuclear cells | |
| NOD/Shi-scid-IL2rγ(null) (NOG), bearing human IL3 and GM-CSF genes (NOG IL3/GM-Tg) | NSG expressing human IL3 and GM-CSF | iv: 4–5 × 104 CD34+ HSCs | id 0.5 μg anti-NP cIgE | iv 500 μg NP-BSA | Local mast cell response Increase in number of mature basophils and mast cells expressing human FcεRI | |
| id serum from pollinosis patients | 200 JAU/mL cedar pollen extract | |||||
| NSG-SCF/GM-CSF/IL3 (NSG-SGM3) | NSG expressing human IL3, GM-CSF, and SCF | Human thymus, liver, and hematopoietic stem cells | PCA: id (ear) 10 ng anti-NP cIgE | PCA: iv 500 μg NP-BSA | PCA: increase in ear thickness | |
| PSA: iv 1.6 μg anti-NP cIgE | PSA: iv 500 μg NP-BSA | PSA: decrease in core body temperature human IgE dependent degranulation of mast cells | ||||
| NSG-SCF | NSG expressing human SCF | iv: 5 × 104–105 CD34+ HSCs derived from cord blood | Weeks 0–7: ig 5 mg peanut protein weekly | Week 8: ig feeding with 78 mg peanut protein | Expansion of human mast cells in the jejunum Expression of human tryptase in the serum Allergen-specific human IgE in the serum | |
| IgER-TG | Express human FCER1A | None | Days 0 and 14: ip 100 μg OVA with aluminum hydroxide | Days 28–38: ig 50 mg OVA on alternating days | Increase in human IgE-bound dendritic cells in the spleen and mesenteric lymph nodes Decreased inflammation in lamina propria Decreased expression of mast cell specific proteases MCPT1, MCPT2, and CPA3 Decreased Th2 cytokines IL4 and IL13 |
BSA, bovine serum albumin; cIgE, chimeric IgE; FCER1A, high affinity immunoglobulin epsilon receptor subunit alpha; FcεRI, high-affinity IgE receptor; HSCs, hematopoietic stem cells; id, intradermal; ig, intragastric; ip, intraperitoneal; iv, intravenous; JAU, Japanese allergy units; OVA, ovalbumin; NP, 4-(hydroxy-3-nitro-phenyl) acetyl; PBMCs, peripheral blood mononuclear cells; PCA, passive cutaneous anaphylaxis; PSA, passive systemic anaphylaxis; SCF, stem cell factor.
Mouse Strains Expressing Human FCER1A
| Mouse strains | Mast cells and basophils | Dendritic cells | Reference |
|---|---|---|---|
| C57BL/6J | αmuβγ2 | No expression | |
| MuFcer1a-/- | No expression | No expression | |
| huFCER1AHPTG × muFcer1a-/- (HP-TG) | αhuβγ2 | αhuγ2 | |
| huFCER1A(Cd11c)TG (Cd11c-TG) | αmuβγ2 | αhuγ2 | |
| huFCERIA(Cd11c)TG × muFcer1a-/- (αDC-TG) | No expression | αhuγ2 |
hu, human; mu, murine; TG, transgenic.